<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>EBV is an oncogenic herpesvirus associated with a number of human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The consistent presence of the EBV genome in certain <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> offers the potential for novel EBV-targeted therapies </plain></SENT>
<SENT sid="2" pm="."><plain>EBV can infect cells in either a latent or lytic form </plain></SENT>
<SENT sid="3" pm="."><plain>Here we demonstrate that a variety of chemotherapeutic agents, including cis-<z:chebi fb="240" ids="33364,33400">platinum</z:chebi>, <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU), and <z:chebi fb="6" ids="45863">taxol</z:chebi>, induce the switch from the latent to lytic form of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>This effect requires the protein kinase C delta, phosphatidylinositol 3'-kinase, and p38 stress <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase signaling pathways but not caspase 3 activation </plain></SENT>
<SENT sid="5" pm="."><plain>Because the lytic but not latent form of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> converts the cytotoxic <z:chebi fb="0" ids="50266">prodrug</z:chebi>, <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> (GCV), into its active form, we examined whether the combination of GCV and chemotherapy is more effective than chemotherapy alone for killing EBV-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>GCV significantly enhanced the ability of 5-FU and cis-<z:chebi fb="240" ids="33364,33400">platinum</z:chebi> to kill EBV-positive, but not EBV-negative, gastric <z:mp ids='MP_0002038'>carcinoma</z:mp> cells in vitro </plain></SENT>
<SENT sid="7" pm="."><plain>Most importantly, the combination of GCV and 5-FU (or GCV and cis-<z:chebi fb="240" ids="33364,33400">platinum</z:chebi>) was much more effective in the treatment of EBV-positive nasopharyngeal <z:mp ids='MP_0002038'>carcinomas</z:mp> passaged in <z:mp ids='MP_0003815'>nude</z:mp> mice than either agent alone </plain></SENT>
<SENT sid="8" pm="."><plain>These data suggest that GCV enhances the efficacy of conventional chemotherapy for the treatment of EBV-positive epithelial cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>